With Vectibix® almost 2 out of 3 patients experienced tumour shrinkage within 8 weeks after starting therapy, which can facilitate surgical resection and improvement of quality of life.*1-4

*In patients with symptoms at baseline

References:

  1. Carrato A, et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017;81:191-202.
  2. Douillard JY, et al. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer 2015;51(10):1231-1242.
  3. Rivera F, et al. Final analysis of the randomised peak trial: overall survival and tumour responses during first-line treatment with mfolfox6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. lnt J Colorectal Dis 2017. doi:10.1007/s00384-017-2800-1.
  4. Siena S, et al. Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. ESMO Open 2016;1:e000041.